Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Genetic Testing

Published by Global Industry Analysts, Inc. Product code 236763
Published Content info 573 Pages
Delivery time: 1-2 business days
Price
Back to Top
Genetic Testing
Published: May 1, 2021 Content info: 573 Pages
Description

Abstract:

Global Genetic Testing Market to Reach $17.3 Billion by 2026

Genetic testing broadly refers to the analysis of genes by examining genetic material taken from cells in a person`s blood sample, or a sample of other body fluids. The growing accessibility and acceptance of non-targeted sequencing among patients and consumers is expected to provide a major stimulus to the market. Applications such as tumor molecular profiling like liquid biopsies to select cancer treatment, non-invasive prenatal diagnostics, and sequencing for diagnosis of rare disease hold tremendous value. The market is poised to benefit from growing popularity of DTC testing for specific health risks like 3 BRCA mutations. Another driver for the market is proliferation of hybrid laboratories combining DTC and conventional laboratories.

Amid the COVID-19 crisis, the global market for Genetic Testing estimated at US$10.6 Billion in the year 2020, is projected to reach a revised size of US$17.3 Billion by 2026, growing at a CAGR of 8.6% over the analysis period. Prenatal & Newborn, one of the segments analyzed in the report, is projected to record a 8.8% CAGR and reach US$6.4 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Diagnostic segment is readjusted to a revised 8.2% CAGR for the next 7-year period. Globally, prenatal testing market is expected to rise due to the increasing risk of chromosomal abnormalities associated with increasing maternal age. One of the key growth drivers for new born and prenatal genetic testing is increased awareness about different chromosomal and genetic disorders. Development of healthcare technologies like HTS and next generation sequencing has helped detection of a number of abnormalities at early stages. Diagnostic genetic testing detects the presence of a certain genetic disease, like Huntington`s disease or cystic fibrosis through the detection of specific gene alteration.

The U.S. Market is Estimated at $4.7 Billion in 2021, While China is Forecast to Reach $1.2 Billion by 2026

The Genetic Testing market in the U.S. is estimated at US$4.7 Billion in the year 2021. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2026 trailing a CAGR of 10.8% over the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.2% and 8.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.4% CAGR. The US is the largest market for genetic testing worldwide. Insurance coverage for all types of genetic testing has increased, and this combined with the factor of significant reductions in genetic testing costs, is expected to result in stronger growth for the market in the years ahead. The market is also witnessing strong regulatory support especially for DTC-genetic testing. Growth in the Europe market is being driven by increasing healthcare expenditure and growing autoimmune diseases prevalence. Asia-Pacific region is expected to witness robust growth due to increasing disposable incomes, and expanding healthcare availability.

Predictive & Presymptomatic Segment to Reach $3 Billion by 2026

Predictive diagnostics is rapidly assuming importance owing to the increasing awareness and growth in preventive medicine. Development in predictive diagnostics is also a result of the growing interest in personalized medicine. Breast cancer diagnosis is one of the key end-use markets targeted by developers of predictive diagnostics. Presymptomatic tests determine the susceptibility of an individual in future, irrespective of his/her existing health condition. In the global Predictive & Presymptomatic segment, USA, Canada, Japan, China and Europe will drive the 9.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.5 Billion in the year 2020 will reach a projected size of US$2.9 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$169.2 Million by the year 2026.

Select Competitors (Total 249 Featured) -

  • 23andMe, Inc.
  • Abbott Laboratories
  • AutoGenomics, Inc.
  • Biocartis NV
  • BioRad Laboratories
  • Cepheid Inc.
  • ELITech Group SAS
  • Illumina, Inc.
  • Laboratory Corporation of America Holdings
  • Luminex Corporation
  • Natera, Inc.
  • PerkinElmer, Inc.
  • QIAGEN N.V.
  • Quest Diagnostics, Inc.
  • Roche Diagnostics AG
  • Roche Molecular Diagnostics, Inc.
  • Thermo Fisher Scientific Inc.
Table of Contents
Product Code: MCP-1392

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • A Prelude to Genetic Testing
    • Top Ten Genetic Diseases Worldwide
    • Different Types of Genetic Tests include
    • Prenatal and Newborn Screening
    • Diagnostic Testing
    • Predictive & Presymptomatic Testing
    • Carrier Identification
    • Pharmacogenomic Testing
    • List of Genetic Disorders by Event, Genetic Manifestation and Prevalence
    • Genetic Testing Delivery Models
    • Genetic Sequencing Approaches
    • Genetic Testing Market Witnesses Sluggish Growth during COVID-19, Set to Record Exponential Growth Post-COVID
    • Expanding Applications to Drive Genetic Testing Market
    • Regional Landscape
    • Prenatal Testing Market to Rise
    • Market Outlook
  • 2. FOCUS ON SELECT PLAYERS
    • Recent Market Activity
    • World Brands
    • Innovations
  • 3. MARKET TRENDS & DRIVERS
    • Studies Indicate Possible Correlation between Genetic Variations Tied to Immunity and COVID-19 Severity
  • SEGMENT ANALYSIS
    • Prenatal Testing - Changing the World of Pregnancy Care
    • List of Available Prenatal Screening and Diagnostic Tests by Indication
    • Players in the Prenatal and New Born Genetic Testing Market
    • Conventional Invasive Pre-Natal Diagnostic Techniques - A Risky Affair
    • Emergence of Non-Invasive Prenatal Diagnosis (NIPD)
    • Competition Intensifies in the NIPD Market
    • Select Commercially Available NIPD (Genetic) Tests for Aneuploidy in the US
    • Strain on Resources Prevent Wide Adoption of Expanded Carrier Sequencing
    • Predictive Diagnostics
    • Breast Cancer Gene Testing Market to Expand Strongly
    • Myriad Genetics - A Leader in Breast Cancer Testing
    • Discovery of Novel Biomarkers Crucial to Predictive Diagnostics
    • Pharmacogenomics Development Augurs Growth of Genetic Testing Market
  • MARKET TRENDS AND GROWTH DRIVERS
    • Genetic Testing Paves the Way for Personalized Medicine
    • TABLE 1: Drug Ineffectiveness for Select Therapeutic Categories - Necessitating Personalized Medic
    • Next-Generation Sequencing (NGS) - A Giant Leap in Genome Sequencing
    • Biomarker Discovery Leads to Advanced Genetic Testing
    • Select List of Available Tumor Markers
    • Immense Popularity of Ancestry Testing
    • Increasing Focus on Data Churning
    • Genetic Testing to Explode into Provider Workflow with Intriguing Use Cases
    • Primary Factors Responsible for Waning Interest in Direct-to Consumer Genetic Testing
    • Liquid Biopsy to Facilitate Cancer Diagnosis and Treatment
    • Hybrid Labs to Bridge Gap Between Traditional and DTC Models
    • Rising Prevalence of Cancer and Chromosomal Disorders Augments Demand for Cell-Free DNA Testing
    • Emergence of Rapid DNA Testing
    • Oncology - A Key Focus Area for Genetic Testing
    • EXHIBIT 1: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
    • Ageing Demographics to Drive Demand for Genetic Testing
    • EXHIBIT 12: Expanding Elderly Population Worldwide: Breakdown of Number of People Aged 65+ Years in Million by Geographic Region for the Years 2019 and 2030
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Genetic Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Genetic Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Genetic Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Prenatal & Newborn by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Prenatal & Newborn by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Prenatal & Newborn by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Diagnostic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Diagnostic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Diagnostic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Predictive & Presymptomatic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Predictive & Presymptomatic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Predictive & Presymptomatic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Carrier by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Carrier by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Carrier by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Pharmacogenomic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Pharmacogenomic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Pharmacogenomic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 22: World Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 23: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 24: World 15-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 25: World Current & Future Analysis for Genetic Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 26: World Historic Review for Genetic Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 27: World 15-Year Perspective for Genetic Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 28: World Current & Future Analysis for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 29: World Historic Review for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 30: World 15-Year Perspective for Cardiovascular Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 31: World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 32: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 33: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • Use of Genomic Data in Clinical Settings to Gather Pace
    • The United States: Leading Market for Genetic Testing Globally
    • Predictive Screening: Another Growth Area
    • Growing Relevance of Personalized Medicine Augurs Well
    • Rising Incidence of Cancer in the US: Driver for Cancer Genetic Testing
    • Estimated Number of New Cancer Cases and Deaths in the US (2019)
    • Newborn Testing Gains Ground
    • Invasive Prenatal Diagnosis Gives Way to Non-Invasive Prenatal Testing
    • Coverage of NIPT in Average Risk Pregnancies Expands Target Market
    • Direct-to-Consumer Testing: A Growing Market
    • Favorable Reimbursement Policies
    • Favorable Insurance Coverage for Cystic Fibrosis Genetic Testing
    • Demographic Changes Offer Growth Opportunities
    • TABLE 14: North American Aging Population by Age Group: 1975-2050
    • Skepticism Limits Widespread Adoption of Genetic Testing
    • Competitive Overview
    • Myriad Eyes Diversification and Expansion for Growth
    • Natera Holds Fort in the NIPT Market
    • Invitae Banks on Low Cost Solutions for Expanding Revenues
    • Regulatory Environment
    • Genetic Information Nondiscrimination Act Boosts Genetic Testing
    • Stricter Regulations for DTC Genetic Testing
    • FDA Attempts to Put a Leash around Unapproved DTC Genetic Tests
    • Select Genetic Test Reimbursement Codes
    • Market Analytics
    • TABLE 34: USA Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 35: USA Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 36: USA 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
    • TABLE 37: USA Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 38: USA Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 39: USA 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027
  • CANADA
    • Rising Incidence of Chronic Diseases Spurs Genetic Testing Demand
    • Number of New Cancer Cases in Canada: 2019
    • Regulatory Scenario
    • Market Analytics
    • TABLE 40: Canada Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 41: Canada Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 42: Canada 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
    • TABLE 43: Canada Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 44: Canada Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 45: Canada 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027
  • JAPAN
    • Demographics Drive Market Growth
    • DTC Genetic Testing Regulatory Scenario
    • TABLE 46: Japan Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 47: Japan Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 48: Japan 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
    • TABLE 49: Japan Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Japan Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 51: Japan 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027
  • CHINA
    • Market Overview
    • China Attracts Domestic and Foreign Players
    • Strong Focus on Genomics
    • Genetic Testing to Reveal Real Talent in Children - A New Popular Application
    • China to Take Lead in Rapidly Growing Asian Genomics Market
    • Market Analytics
    • TABLE 52: China Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 53: China Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 54: China 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
    • TABLE 55: China Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 56: China Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 57: China 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027
  • EUROPE
    • European Personalized Medicine Market to Exhibit Robust Growth
    • Aging Population to Drive Demand for Genetic Testing
    • TABLE 28: European Population by Age Group (2016, 2030 & 2050): Percentage Share Breakdown by Age Group for 0-14, 15-64, and 65 & Above
    • Legislations/Regulatory Policies in Select European Countries
    • Legislations Governing Genetic Testing in Select European Countries
    • Rising Cancer Incidence Augurs Well for European Genetic Testing Market
    • Cancer Incidence in Europe: Number of New Cancer Cases (in Thousands) by Site for 2018
    • TABLE 58: Europe Current & Future Analysis for Genetic Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 59: Europe Historic Review for Genetic Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 60: Europe 15-Year Perspective for Genetic Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 61: Europe Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 62: Europe Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 63: Europe 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
    • TABLE 64: Europe Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 65: Europe Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 66: Europe 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 67: France Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 68: France Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 69: France 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
    • TABLE 70: France Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 71: France Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 72: France 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027
  • GERMANY
    • Parliamentary Regulations
    • TABLE 73: Germany Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 74: Germany Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 75: Germany 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
    • TABLE 76: Germany Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 77: Germany Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 78: Germany 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 79: Italy Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 80: Italy Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 81: Italy 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
    • TABLE 82: Italy Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 83: Italy Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 84: Italy 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • Increased Support for Personalized Medicine to Drive Genetic Testing
    • SMIP for Pharmacogenomic Testing
    • Increasing Need for Less Risky Prenatal Diagnostic Methods in the UK
    • Principles for DTC Genetic Testing Laid out by HGC
    • TABLE 85: UK Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 86: UK Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 87: UK 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
    • TABLE 88: UK Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 89: UK Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 90: UK 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 91: Rest of Europe Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Rest of Europe Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 93: Rest of Europe 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
    • TABLE 94: Rest of Europe Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 95: Rest of Europe Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 96: Rest of Europe 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • Healthcare Spending in Asia-Pacific: On the Rise
    • India
    • Australia and New Zealand
    • Market Analytics
    • TABLE 97: Asia-Pacific Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 98: Asia-Pacific Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 99: Asia-Pacific 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
    • TABLE 100: Asia-Pacific Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 101: Asia-Pacific Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 102: Asia-Pacific 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027
  • REST OF WORLD
    • Predictive Screening: Another Growth Area
    • Market Analytics
    • TABLE 103: Rest of World Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 104: Rest of World Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 105: Rest of World 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
    • TABLE 106: Rest of World Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 107: Rest of World Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 108: Rest of World 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 249
Back to Top